Mannkind Corp (MNKD) 5.44 $MNKD Too Good to Be True?

New Post Public Reply Private Reply Replies (0) Message Board

Mar 16, 2015 at 2:06 PM

Mannkind Corp (MNKD) 5.44 $MNKD

Too Good to Be True? Proceed With Caution on These 2 Biotechs
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 14, 11:02AM CDT
Tune in to this health care edition of Industry Focus for a look at two small biotechs that sound exciting -- and may in fact prove to be the next big thing -- but which currently face enough challenges that most Fools probably won't want to rush in....
OREX: 6.96 (-0.08), PTLA: 41.34 (+0.64), NVO: 48.88 (+1.28), VVUS: 2.99 (+0.17), SNY: 48.63 (+1.56), MNKD: 5.44 (-0.07), ARNA: 4.76 (-0.05)

A Look At Afrezza Prescriptions Through Week 6 And Predictions Through Week 10
Austin Moss - at Seeking Alpha - Fri Mar 13, 1:54PM CDT

MNKD: 5.44 (-0.07), SNY: 48.63 (+1.56)

Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.65 (-0.24), ZIOP: 13.12 (-0.20), UNIS: 3.52 (-0.20), FCSC: 5.29 (-0.10), XON: 45.63 (-0.86), MNKD: 5.44 (-0.07)

Interesting MNKD Put Options For May 1st
DividendChannel.com - Thu Mar 12, 10:54AM CDT
Investors in MannKind Corp saw new options become available today, for the May 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new May 1st contracts and identified the...
MNKD: 5.44 (-0.07)

Generex successful in increasing insulin concentration in spray product candidate
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 10:44AM CDT

MNKD: 5.44 (-0.07)

Coverage of Biotech Equities -- MannKind, Novavax, Curis, Pharmacyclics, and Alexion Pharma
PR Newswire - Tue Mar 10, 8:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRIS: 2.93 (-0.09), PCYC: 256.00 (+1.02), NVAX: 9.42 (+0.13), ALXN: 178.35 (+1.46), MNKD: 5.44 (-0.07)

A Close-Up Look At The Report That Had MannKind Investors Reeling
George Rho - at Seeking Alpha - Mon Mar 09, 11:36AM CDT

MNKD: 5.44 (-0.07)

Mannkind: Flawed? No Competition? Overall Superior Drug?
Looking For Diogenes - at Seeking Alpha - Mon Mar 09, 8:07AM CDT

MNKD: 5.44 (-0.07)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 4:42PM CST

VEEV: 25.04 (+0.18), NG: 3.03 (-0.10), CRIS: 2.93 (-0.09), EVTC: 22.09 (-0.15), GTN: 14.44 (+0.40), SM: 43.67 (+0.11), MNKD: 5.44 (-0.07), RIGL: 3.43 (-0.17), EXK: 1.77 (+0.08), WBAI: 11.83 (+0.23)

Seeking Alpha's Biotech Weekly: AbbVie - Pharmacyclitics, Orexigen Confusion, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
PCYC: 256.00 (+1.02), MDT: 77.59 (+1.12), ARWR: 7.38 (-0.15), SPHS: 0.57 (+0.01), BSX: 17.34 (+0.73), MDVN: 129.97 (+1.30), JNJ: 100.73 (+1.52), AAC: 28.24 (+0.50), ABBV: 58.83 (+0.83), SNY: 48.63 (+1.56), SMMT: 10.81 (+0.11), ARNA: 4.76 (-0.05), XLRN: 41.20 (unch), MNK: 126.09 (+1.97), AQXP: 11.64 (-0.44), PFE: 34.44 (+0.44), AMGN: 161.80 (+7.54), GSK: 46.93 (+0.56), BMY: 67.83 (+0.96), MNKD: 5.44 (-0.07), CELG: 120.39 (+2.66), OREX: 6.96 (-0.08), PODD: 35.60 (+0.52), GERN: 4.15 (-0.19), TEVA: 60.63 (+0.63), TCON: 14.89 (+1.14), NVS: 97.92 (+0.88)

Technical Analysis of Wal-Mart, Coca-Cola, MannKind and Las Vegas Sands
Kumar Abhishek - Amigobulls - Thu Mar 05, 7:02AM CST
Coca-Cola stock price has again found support at 100 day SMA. The 100 day SMA has provided support to coca cola stock price on multiple occasions.
KO: 40.15 (+0.24), WMT: 83.19 (+1.29), LVS: 52.98 (+0.61), MNKD: 5.44 (-0.07)

5 Things MannKind Corporation's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 05, 6:21AM CST
MannKind 's fourth-quarter conference was only 31 minutes long, but the call contained some tidbits of insight from the biotech's management that investors should know. Source: MannKind. "In fact, we were just, the other day, asked if we...
SNY: 48.63 (+1.56), MNKD: 5.44 (-0.07)

MannKind: Use This Drop As An Opportunity
Kumquat Research - at Seeking Alpha - Wed Mar 04, 7:33AM CST

MNKD: 5.44 (-0.07)

MannKind's Charts Suggest Waiting on the Stock After Goldman's Downgrade
at The Street - Tue Mar 03, 3:22PM CST
Here's a technical look at the stock after a brutal downgrade.
MNKD: 5.44 (-0.07)

New Buy Ins And Profit Taking: The Well-Valued Growth Portfolio This Month
Psycho Analyst - at Seeking Alpha - Tue Mar 03, 1:05PM CST

ODFL: 79.32 (+1.13), ESRX: 83.44 (+2.07), THO: 62.03 (+0.37), SWKS: 96.15 (+3.23), LGIH: 14.49 (-0.10), LKQ: 24.56 (+0.14), DG: 75.38 (+1.08), MNKD: 5.44 (-0.07), LUV: 45.28 (+0.77)

Why MannKind Corp. Stock Crashed Today
George Budwell, The Motley Fool - Motley Fool - Tue Mar 03, 10:48AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of MannKind Corp. fell by more than 14% on...
GS: 192.03 (+2.69), SNY: 48.63 (+1.56), MNKD: 5.44 (-0.07)

Potential Afrezza discounts and challenging competitive landscape behind Goldman downgrade of MannKind
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 10:46AM CST

LLY: 71.08 (+1.19), SNY: 48.63 (+1.56), MNKD: 5.44 (-0.07)

Cramer: Goldman's Negative MannKind Report Creates 'Problematic Situation'
at The Street - Tue Mar 03, 10:28AM CST
Cramer says the negative Goldman Sachs is having an unhealthy effect on MannKind's stock.
MNKD: 5.44 (-0.07)

Forget Biased Analysts, Diabetics Love MannKind's Afrezza
Maredin Capital Advisors - Seeking Alpha - Tue Mar 03, 9:32AM CST
The MannKind (ticker " MNKD "

story/plot continues to thicken Over the past several years, investors, both long and short, have had to rely on trial data, and the opinions of analysts to guide their investment decisions. This led to a...
MNKD: 5.44 (-0.07)

MannKind off 10% premarket on Goldman downgrade
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:24AM CST

MNKD: 5.44 (-0.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Larry Ellison's Moves Signal Confidence in Oracle's Future

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Protecting Teeth: Insights from Endodontist Dr. Joubert

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Ajman Spotlights Tourism at Arabian Travel Market 2026

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

USPS Honors 150 Years of the U.S. Coast Guard Academy

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Damp or Dry: The Battle for Healthy Air in Colorado

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...